Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to CN¥19.35, the stock trades at a trailing P/E ratio of 65.2x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 64% over the past three years. Buy Or Sell Opportunity • Jul 30
Now 25% undervalued after recent price drop Over the last 90 days, the stock has fallen 20% to CN¥15.87. The fair value is estimated to be CN¥21.16, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 7.3%. Valuation Update With 7 Day Price Move • Jul 16
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CN¥22.38, the stock trades at a trailing P/E ratio of 75.5x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 78% over the past three years. Annuncio • Jun 30
Shanghai Aladdin Biochemical Technology Co.,Ltd. to Report First Half, 2026 Results on Aug 20, 2026 Shanghai Aladdin Biochemical Technology Co.,Ltd. announced that they will report first half, 2026 results on Aug 20, 2026 Buy Or Sell Opportunity • Jun 29
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 54% to CN¥25.94. The fair value is estimated to be CN¥21.32, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 7.3%. Board Change • May 20
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Ru Shi Ma was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Apr 28
Shanghai Aladdin Biochemical Technology Co.,Ltd., Annual General Meeting, May 19, 2026 Shanghai Aladdin Biochemical Technology Co.,Ltd., Annual General Meeting, May 19, 2026, at 14:30 China Standard Time. Location: 16F, South Tower, No. 36, Xinjinqiao Road, Pudong New Area, Shanghai China Annuncio • Mar 30
Shanghai Aladdin Biochemical Technology Co.,Ltd. to Report Q1, 2026 Results on Apr 28, 2026 Shanghai Aladdin Biochemical Technology Co.,Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 Annuncio • Dec 26
Shanghai Aladdin Biochemical Technology Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026 Shanghai Aladdin Biochemical Technology Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026 Annuncio • Sep 30
Shanghai Aladdin Biochemical Technology Co.,Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Shanghai Aladdin Biochemical Technology Co.,Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Annuncio • Jun 30
Shanghai Aladdin Biochemical Technology Co.,Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Shanghai Aladdin Biochemical Technology Co.,Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 Annuncio • Apr 25
Shanghai Aladdin Biochemical Technology Co.,Ltd., Annual General Meeting, May 15, 2025 Shanghai Aladdin Biochemical Technology Co.,Ltd., Annual General Meeting, May 15, 2025, at 14:30 China Standard Time. Location: 16F, South Tower, No. 36, Xinjinqiao Road, Pudong New Area, Shanghai China Annuncio • Mar 28
Shanghai Aladdin Biochemical Technology Co.,Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Shanghai Aladdin Biochemical Technology Co.,Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Annuncio • Dec 27
Shanghai Aladdin Biochemical Technology Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025 Shanghai Aladdin Biochemical Technology Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.09 (vs CN¥0.085 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.09 (up from CN¥0.085 in 3Q 2023). Revenue: CN¥139.1m (up 43% from 3Q 2023). Net income: CN¥25.3m (up 6.4% from 3Q 2023). Profit margin: 18% (down from 24% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥13.08, the stock trades at a trailing P/E ratio of 34.7x. Average forward P/E is 16x in the Chemicals industry in China. Negligible returns to shareholders over past year. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Annuncio • Sep 30
Shanghai Aladdin Biochemical Technology Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Shanghai Aladdin Biochemical Technology Co.,Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥11.56, the stock trades at a trailing P/E ratio of 31.4x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 13% over the past year. Reported Earnings • Aug 31
Second quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.053 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.10 (up from CN¥0.053 in 2Q 2023). Revenue: CN¥140.0m (up 42% from 2Q 2023). Net income: CN¥30.2m (up 121% from 2Q 2023). Profit margin: 22% (up from 14% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Annuncio • Jun 29
Shanghai Aladdin Biochemical Technology Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024 Shanghai Aladdin Biochemical Technology Co.,Ltd. announced that they will report first half, 2024 results on Aug 31, 2024 Annuncio • Jun 08
Shanghai Aladdin Biochemical Technology Co.,Ltd. (SHSE:688179) announces an Equity Buyback for CNY 15 million worth of its shares. Shanghai Aladdin Biochemical Technology Co.,Ltd. (SHSE:688179) announces a share repurchase program. Under the program, the company will repurchase up to CNY 15 million worth of its shares. The shares will be repurchased at CNY 16.8 per share. The purpose of the program is to use the repurchased shares for employee stock ownership plans or equity incentives. If the repurchased shares are not used up within 36 months after the announcement of the results of the share repurchase and the share change, the unused repurchased shares will be cancelled. The program will be funded from company's own funds. The program will be valid for 6 months. Reported Earnings • Apr 30
First quarter 2024 earnings released: EPS: CN¥0.09 (vs CN¥0.086 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.09. Revenue: CN¥98.5m (up 14% from 1Q 2023). Net income: CN¥17.1m (flat on 1Q 2023). Profit margin: 17% (down from 20% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Reported Earnings • Feb 26
Full year 2023 earnings released: EPS: CN¥0.42 (vs CN¥0.46 in FY 2022) Full year 2023 results: EPS: CN¥0.42 (down from CN¥0.46 in FY 2022). Revenue: CN¥403.1m (up 6.6% from FY 2022). Net income: CN¥83.3m (down 9.8% from FY 2022). Profit margin: 21% (down from 24% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Chemicals industry in China. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥13.48, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 13x in the Chemicals industry in China. Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥19.97, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 15x in the Chemicals industry in China. New Risk • Oct 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.0% average weekly change). Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.074 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.12 (up from CN¥0.074 in 3Q 2022). Revenue: CN¥97.3m (up 10% from 3Q 2022). Net income: CN¥23.8m (up 56% from 3Q 2022). Profit margin: 24% (up from 17% in 3Q 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.074 (vs CN¥0.099 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.074 (down from CN¥0.099 in 2Q 2022). Revenue: CN¥98.9m (up 16% from 2Q 2022). Net income: CN¥13.7m (down 29% from 2Q 2022). Profit margin: 14% (down from 23% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Annuncio • Jun 28
Shanghai Aladdin Biochemical Technology Co.,Ltd. to Report First Half, 2023 Results on Aug 29, 2023 Shanghai Aladdin Biochemical Technology Co.,Ltd. announced that they will report first half, 2023 results on Aug 29, 2023 Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.22 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.12 (down from CN¥0.22 in 1Q 2022). Revenue: CN¥86.5m (down 5.9% from 1Q 2022). Net income: CN¥17.3m (down 44% from 1Q 2022). Profit margin: 20% (down from 34% in 1Q 2022). The decrease in margin was primarily driven by higher expenses. Board Change • Mar 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of the Board & GM Jiuzhen Xu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 
